Curis Lifesciences IPO is an SME public issue opening on November 7, 2025, and closing on November 11, 2025. The IPO price band is set at ₹120 to ₹128 per share and aims to raise approximately ₹27.52 crores. Curis Lifesciences is a pharmaceutical manufacturer based in Ahmedabad, operating a WHO-GMP-certified facility producing diverse formulations including tablets, capsules, oral liquids, and sterile ophthalmic ointments. Curis Lifesciences IPO presents a niche opportunity in pharma manufacturing with capacity expansion and international market focus.
₹00
₹128
₹
Expert Opinions
Market sentiment for Curis Lifesciences IPO is optimistic, driven by the company’s strong presence in the pharmaceutical manufacturing sector and consistent financial performance. The company’s strengths include a WHO-GMP-certified manufacturing facility, diverse product portfolio, and established client base serving over 100 pharmaceutical firms. Risks involve regulatory changes in the pharma industry and competition pressure in domestic and international markets.
Valuation analysis of Financial Year 2025 highlights Curis Lifesciences IPO with an impressive Return on Equity (ROE) of 55.25%, ROCE of 27.83%, and Net Asset Value (NAV) of ₹27.34, reflecting robust profitability and asset utilization. From a long-term investment perspective, the IPO offers a valuable opportunity to participate in pharma sector growth driven by increasing demand and export potential, while investors should remain mindful of industry cyclicality and operational risks.
Investor Considerations
Investor considerations for Curis Lifesciences IPO highlight steady company performance with revenues growing from ₹35.87 crores in FY 2023 to ₹49.65 crores in FY 2025 and a PAT margin of 12.43%. The pharmaceutical sector outlook remains strong due to consistent demand for diversified formulations and export opportunities. Curis Lifesciences IPO valuation in FY 2025 shows a high Price to Book Value of 12.64, and manageable Debt to Equity ratio of 0.96, indicating sound financial health.
Growth prospects stem from capacity expansion, international market focus, and scalable manufacturing capabilities. Risks include regulatory hurdles, competition, and price sensitivity in pharma markets. This IPO suits long-term investors aiming to leverage pharma sector growth, while short-term investors should consider market conditions.
| Date | GMP | Trend |
|---|---|---|
| 01 Nov 2025 15.39 | ₹00 | --- |
| 31 Oct 2025 12.34 | ₹00 | --- |
FAQs
Curis Lifesciences IPO Current GMP is ₹00.
Curis Lifesciences IPO Expected Returns is 0.00%.
Curis Lifesciences IPO estimated listing price is ₹128.